WHO Prequalifies Celltrion’s Rituximab
Truxima Becomes Second Biosimilar To Be Prequalified By Organization
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
You may also be interested in...
The World Health Organization has recently added further biosimilar versions of trastuzumab to its list of prequalified products, along with Roche’s original trastuzumab and rituximab brands, Herceptin and MabThera/Rituxan.
In the first in a series of exclusive interviews, IGBA chair Hanan Sboul talks about the international off-patent industry association’s collaboration with the WHO and how it is expected to develop in future.
Samsung Bioepis’ Ontruzant trastuzumab biosimilar has become the first biosimilar to be prequalified by the World Health Organization.